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The changes that occur in cell dynamics following oncogenic mutation that lead to 20 
the development of tumours are currently unknown. Here, using skin epidermis as 21 
a model, we assessed the impact of oncogenic hedgehog signalling in distinct cell 22 
populations and their capacity to induce basal cell carcinoma, the most frequent 23 
cancer in humans. We found that only stem cells, and not progenitors, were 24 
competent to initiate tumour formation upon oncogenic hedgehog signalling. 25 
Interestingly, this difference was due to the hierarchical organization of tumour 26 
growth in oncogene-targeted stem cells, characterized by an increase of symmetric 27 
self-renewing divisions and a higher p53-dependent resistance to apoptosis, leading 28 
to rapid clonal expansion and progression into invasive tumours. Our work reveals 29 
that the capacity of oncogene-targeted cells to induce tumour formation is not only 30 
dependent on their long-term survival and expansion, but also on the specific 31 
clonal dynamics of the cancer cell of origin.  32 
 33 
34 
 3
Introduction 35 
Cancer arises through the acquisition of oncogenic mutations1. How such 36 
oncogenic mutations impact on the rate of stem and progenitor cell proliferation and the 37 
proportion of divisions that result in symmetric and asymmetric fate is currently poorly 38 
understood. Recent studies following oncogenic activation in mouse gut prior to tumour 39 
formation showed that intestinal stem cells (SCs) acquire a proliferative advantage over 40 
their wildtype neighbours, leading to precocious clonal fixation of mutant crypts2,3. 41 
However, the question of whether and how mutant crypts expand and progress into 42 
invasive tumours remains unknown.  43 
 44 
Basal cell carcinoma (BCC) is the most frequent tumour in humans with more 45 
than 5 million new cases diagnosed each year worldwide. BCCs arise from the 46 
constitutive activation of the hedgehog (HH) pathway through either Patched (Ptch) loss 47 
of function or Smoothened (Smo) gain of function4. Different mouse models of BCC 48 
using Ptch1 deletion or oncogenic SmoM2 mutant expression induce the formation of 49 
tumours that resemble superficial human BCC5. The skin epidermis contains distinct 50 
types of SCs that contribute to the homeostasis of discrete regions of epidermis6. 51 
Interfollicular epidermis (IFE) is maintained by SCs targeted by K14-CreER and 52 
committed progenitors (CPs) targeted by Inv-CreER in tail, ear, back and ventral skin 53 
epidermis7,8. Activation of oncogenic HH signalling through SmoM2 expression or 54 
Patched1 deletion in these different tissues using K14-CreER, which targets both SCs 55 
and CPs, induce BCC formation7,9-12. However, the question of whether and how 56 
SmoM2 expression in SCs and/or CPs drives BCC formation remains unresolved.  57 
 58 
 59 
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Results 60 
SCs but not CPs initiate BCC formation  61 
To determine whether SCs and CPs are both competent to induce BCC, we induced 62 
oncogenic SmoM2 expression exclusively in CPs using Inv-CreER, and in both CPs 63 
and SCs using K14-CreER7 at the same clonal density (Fig.1a and Extended Data 64 
Fig.1a). As previously reported, activation of SmoM2 expression using K14-CreER 65 
induced BCC, characterized by invasion into the dermis and branched morphology, in 66 
both tail and ear epidermis (Fig. 1b)9-11. In sharp contrast, activation of SmoM2 67 
expression in CPs using Inv-CreER lead to preneoplastic lesions (including hyperplasia 68 
and dysplasia) that did not progress into BCCs (Fig. 1b). These results suggest that only 69 
IFE-SCs are competent to induce BCC following SmoM2-activation while IFE-CPs are 70 
highly resistant.  71 
 72 
We then assessed whether the competence of SCs and CPs to initiate BCC was 73 
dependent on the oncogene or tumor suppressor gene used to activate HH signalling. To 74 
this end, we induced Ptch1 deletion using K14- or Inv-CreER (Fig. 1c). Ptch1 deletion 75 
using K14-CreER lead to BCCs arising from the IFE and the infundibulum (Fig. 1c). In 76 
contrast, Ptch1 deletion using Inv-CreER, which targets some basal cells in the back and 77 
ventral skin epidermis8, did not lead to the rapid development of BCC, and only rare 78 
and small BCCs were observed 24w post-induction (Fig. 1c-d). These results reveal that 79 
only IFE/infundibulum SCs are competent to induce BCC formation whereas CPs are 80 
highly resistant, irrespective of the oncogene or tumour suppressor gene used to activate 81 
HH signalling and body location (tail, ear, back and ventral skin).  82 
 83 
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 Two distinct self-maintained compartments, scale and interscale, have been 84 
described in tail epidermis13. To assess whether cells located in these two compartments 85 
respond equally to oncogenic activation, we performed immunofluorescence using a 86 
scale-specific marker (K31) and SmoM2-YFP on whole mount tail epidermis. 87 
Interestingly, we found that BCCs arose from K14-CreER SmoM2 targeted cells 88 
located only in the interscale (Fig. 1e). K14 clones in the interscale progressively lost 89 
their normal differentiation program, as evidenced by the loss of spinous-like cells, 90 
became hyperplastic, then dysplastic (Fig. 1f and Extended Data Fig. 1b-c).  From 4 to 8 91 
weeks (w) post-induction, around 15% of clones had progressed into BCC in interscale, 92 
increasing to 40% after 24w (Fig. 1e-f). In contrast, K14 clones in scale never 93 
progressed to BCC, and maintained a normal differentiation program for an extended 94 
period, despite clonal expansion mediated by SmoM2 expression (Fig. 1e-f and 95 
Extended Data Fig. 1b-c). 96 
 97 
 Together, these data indicate that the fate of oncogene targeted cells and the 98 
ability of these cells to progress into BCC depends both on their location (scale versus 99 
interscale) and cellular origin (SC versus CP). This prompted us to ask whether there 100 
are regional differences in SC potential in tail epidermis even under homeostatic 101 
conditions.  102 
Homeostasis of the interscale epidermis  103 
To gain quantitative insight into regional variation in SC potential, we performed 104 
lineage tracing at homeostasis to determine whether scale and interscale are 105 
differentially maintained. To this end, we compared the evolution of K14-CreER/Rosa-106 
YFP and Inv-CreER/Rosa-YFP targeted cells at single cell resolution over a 24w time-107 
course. Interestingly, although both broad, the distribution of clone sizes in the two 108 
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regions became increasing divergent (Fig. 2a-b and Extended Data Fig. 2), confirming 109 
the importance of regionalization in cellular dynamics (Supplementary Theory).  110 
 111 
Consistent with our previous study7, the evolution of mean clone size of 112 
progenitors targeted by Inv-CreER in the interscale fits well with the targeting of an 113 
equipotent CP population presenting a small but statistically significant imbalance in 114 
fate towards terminal differentiation (Fig. 2c-d). Similarly, the evolution of mean clone 115 
size for K14-CreER cells is consistent with the targeting of a long-term self-renewing 116 
SC population that divides more slowly than CPs (Fig. 2c-d). To define quantitatively 117 
the dynamics of these two populations (cell cycle times, relative proportion of SCs and 118 
CPs labelled by the K14-CreER and their fate probabilities), we made a joint fit to the 119 
basal and suprabasal mean clone sizes, and extracted optimal parameters and confidence 120 
intervals (Supplementary Theory).  121 
 122 
To independently verify the predictions of the model, the persistence of Inv- and 123 
K14-CreER targeted clones was used to infer the respective labelled cell fraction. As 124 
expected from the labelling of a CP population, for Inv-CreER targeted clones, we 125 
found that the labelled cell fraction decreased over time (Fig. 2e). In contrast, for K14-126 
CreER targeted clones, the labelled cell fraction increased over time, consistent with the 127 
preferential targeting of the SC population (Fig. 2e). Strikingly, we obtained excellent 128 
predictions for the labelled cell fraction for both K14- and Inv-CreER using parameters 129 
extracted independently from a fit to the mean clone sizes (Fig. 2e). These results 130 
provide compelling evidence in favour of a SC and CP hierarchy, and rule out the 131 
possibility that the differences between K14- and Inv-CreER targeted clones are the 132 
consequence of differential short-term “priming” of induced cells (Extended Data Fig. 133 
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3a). Importantly, the hierarchical model also predicted accurately the complete 134 
distribution of clone sizes at all time points (Extended Data Fig. 3b-c) for both K14- and 135 
Inv-CreER. 136 
 137 
In sharp contrast, in the scale region of tail epidermis, both basal and suprabasal 138 
clone size and persistence of K14- and Inv-CreER targeted cells were statistically 139 
indistinguishable (Extended Data Fig. 4a and c). Crucially, the labelled cell fraction did 140 
not change significantly between 2w and 24w post-labelling (Extended Data Fig.4c), an 141 
indication that K14- and Inv-CreER mark the same balanced CP population13. We again 142 
validated the model (Fig.4b) by showing that it could predict quantitatively both the 143 
evolution of clonal persistence, as well the clone size distribution at all time points 144 
(Extended Data Fig. 4b-d).  145 
 146 
 These results show that, during homeostasis, interscale is maintained by two 147 
discrete populations; a comparatively slow-cycling SC and a more rapidly dividing CP 148 
population, whereas scale is maintained by a single CP population. As well as unifying 149 
diverging reports of maintenance hierarchy in tail epidermis7,13,14, these findings raised 150 
the question of whether the restriction of BCCs to the interscale correlated with the 151 
regional localization of IFE SCs. To test this hypothesis, we assessed whether the same 152 
regionalized lineage hierarchy persisted upon SmoM2 activation.  153 
 154 
Oncogene-targeted CPs are frozen into dysplasia  155 
To resolve the cellular dynamics underpinning to the differential sensitivity of SCs and 156 
CPs to BCC initiation in interscale, we first studied the dynamics and proliferation 157 
kinetics of Inv-CreER/Rosa-SmoM2 clones. Oncogenic activation in Inv-CreER CPs 158 
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lead to an increase of the average basal clone size, total clone size and clonal 159 
persistence compared to homeostatic conditions (Fig. 3a-b and Extended Data Fig.5a-c), 160 
as well as abnormal or decreased differentiation (Fig. 3a and Extended Data Fig. 1 b-c). 161 
We assessed the average cell cycle time of SmoM2 Inv-CreER-targeted cells by first 162 
marking proliferating cells using 24h of EdU administration, followed by variable 163 
periods of continuous BrdU administration. From the co-labelling of EdU/BrdU, we 164 
found that CPs divided on average every 3.6±0.5 days at 4w following SmoM2 165 
expression, 7.2±0.6 days at 8w and 9.8±0.3 days at 12w (Fig. 3c), indicating that the 166 
average division rate of SmoM2 CPs decreases with time. Surprisingly, division rates 167 
were uncorrelated with clone size at all time points, indicating that the decrease occurs 168 
independently of clone size or stage of tumour progression (Extended Data Fig. 5d), and 169 
consistent with the Inv-CreER oncogene targeted cells functioning as a single 170 
equipotent population.  171 
 172 
Since deregulation of apoptosis is also important for cancer formation1, we 173 
assessed whether apoptosis influences the clonal dynamics of oncogene targeted CPs. In 174 
common with their normal counterpart, Inv-CreER targeted cells did not show evidence 175 
of apoptosis over the first 6w following SmoM2 expression (data not shown). However, 176 
from 8w on, about 60% of Inv-CreER targeted clones that presented hyperplasia or 177 
dysplasia contained about 2-4% of apoptotic cells as measured by active caspase-3 178 
immunostaining (Fig. 3d, Extended Data Fig. 5e-i).  179 
 180 
Taking these rates (Fig. 3e) as an input, we could obtain an excellent fit to the 181 
average clone size (Fig. 3f) with cell fate probabilities that remain constant over time 182 
(symmetric renewal (PP): asymmetric division (PD): symmetric differentiation 183 
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(DD)=39%:45%:16%) (Fig. 3g). This result demonstrates that oncogenic expression in 184 
CPs leads to enhanced clonal expansion and survival by promoting symmetric 185 
proliferation over terminal differentiation. Such an imbalance would lead to exponential 186 
clone growth if it were not counteracted by an ever-diminishing effective proliferation 187 
rate, leading to a plateau in the mean basal clone size (Fig. 3f). Notably, the model 188 
prediction provided a good fit to the clone size distribution at all time points (Fig. 3h).  189 
 190 
Finally, to further verify the model, a low short-term dose of EdU was used to 191 
mark a minority of dividing cells and their fate outcome was recorded 3 days later by 192 
quantifying the basal and suprabasal localization of EdU doublets (Extended Data Fig. 193 
5j). From these results, we could confirm a large imbalance between symmetric division 194 
and terminal differentiation (35%). 195 
   196 
Since the scale is maintained by a single progenitor pool, we wished to probe 197 
whether its response to oncogenic activation was similar to interscale CPs. Crucially, 198 
after an initial increase, the overall labelled cell fraction remained roughly constant over 199 
time in scale between 8 and 24w, at a similar level for both K14- and Inv-CreER 200 
(Extended Data Fig. 6a-c), suggesting that, in sharp contrast with interscale, both 201 
populations behave identically upon oncogenic activation (Extended Data Fig. 6d). 202 
Together, these results show that both interscale and scale CPs are resistant to BCC 203 
formation upon oncogenic HH signalling, although interscale clones can persist longer 204 
due to a larger fate imbalance and enhanced differentiation defects, while scale clones 205 
rapidly converge towards balance. However, as human epidermis does not show scale 206 
organization, the absence of BCC formation in the scale region might not have human 207 
relevance.  208 
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 209 
Oncogene-targeted SCs progress into BCC  210 
To gain insight into how SmoM2 expression in SCs promotes BCC formation, we then 211 
performed a quantitative analysis of K14-CreER/Rosa-SmoM2 clones. Compared to 212 
Inv-targeted clones, SmoM2 expression in K14-targeted cells lead to a more rapid and 213 
persistent expansion of a fraction of clones (Fig. 4a-b and Extended Data Fig.7a-c) that 214 
progressed into BCC, as well as the formation of smaller clones that did not show 215 
tumour progression (Fig. 1e and 4b). This suggests that, in line with homeostatic 216 
conditions, K14-CreER marks a fraction of tumour-like SCs, together with tumour-like 217 
CPs, a heterogeneity that we verified using proliferation assays (Fig. 4c). Indeed, we 218 
found that one population of K14-CreER targeted cells consisted of small clones that 219 
displayed similar proliferation kinetics as Inv-CreER SmoM2 clones, while a second 220 
population consisted of larger clones, which re-entered cell cycle significantly faster 221 
(Fig. 4c, Extended Data Fig. 5d and 7d). The population of small K14-CreER targeted 222 
clones (dysplasia and hyperplasia) also presented higher levels of apoptosis compared to 223 
the larger clones (Fig. 4d and Extended Data Fig. 7e-i). As a result, even though the 224 
proliferation of the larger clones also decreased with time (Fig. 4e and Extended Data 225 
Fig.7j), their division rate was consistently higher than the Inv-CreER targeted 226 
population (Fig. 4e). 227 
 228 
To model BCC initiation, we adapted the hierarchical model obtained during 229 
homeostasis and fitted jointly the mean basal and suprabasal clone sizes of all K14-230 
CreER-SmoM2 clones, taking as input the division rate as well as the fraction of SCs 231 
initially labelled by the K14-CreER determined from measurements at homeostasis, and 232 
used the fate choices of SCs as fitting parameters (Fig. 4f and Extended Data Fig. 7k). 233 
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In particular, we posited that SCs are imbalanced towards symmetric renewal, whereas 234 
CPs derived from these cells remain slightly imbalanced toward symmetric 235 
differentiation with the same fate probability as in homeostasis, which gave a good fit to 236 
the average basal clone size (Fig. 4g). Notably, the measured clone size distributions 237 
from 12w onwards could not be fit with a one-progenitor population model, in stark 238 
contrast to the distributions of Inv-CreER-SmoM2 clones. Instead, the K14-CreER-239 
SmoM2 clone size distributions displayed a “double-exponential” decay, consistent 240 
with the labelling of two distinct populations, as predicted quantitatively by the model 241 
(Fig. 4h and Supplementary Theory). This shows that K14-CreER targets tumour-like 242 
SCs making imbalanced stochastic fate choices, in addition to targeting the same 243 
tumour-like CP population as Inv-CreER.  244 
 245 
As a finally consistency check, we addressed a key hallmark of the hierarchical 246 
model, that SCs give rise to basal CPs in K14-CreER targeted clones. This predicts that 247 
the fraction of cell divisions resulting in two basal cells should be greater in SC versus 248 
CP-targeted clones. Indeed, short-term EdU pulse-chase experiments revealed that, in 249 
BCC, most divisions (77%) lead to two basal cells (Extended Data Fig. 7l). In dysplasia, 250 
the fraction of two EdU+ basal cell doublets was intermediate between the BCC and 251 
Inv-CreER/Rosa-SmoM2 values (Extended Data Fig. 5j and 7l), consistent with a 252 
mixture of SC and CP-targeted clones.  253 
 254 
P53 restricts CPs to progress into BCC  255 
Given the observed differences in apoptosis and division rates between oncogene 256 
targeted SC and CP, we assessed whether p53, a tumour suppressor gene frequently 257 
mutated in human BCC15 that controls cell cycle arrest and apoptosis16, was 258 
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differentially activated in SCs and CPs upon SmoM2 activation. Immunohistochemistry 259 
revealed that p53 was more frequently found in SmoM2 clones arising from Inv-CreER 260 
as compared to K14-CreER mice (Extended data Fig.8a). To determine whether p53 261 
stabilization in oncogene targeted CPs restricts the potential of these progenitors to 262 
generate BCC, we deleted p53 together with SmoM2 activation and assessed tumour 263 
formation. Interestingly, p53 deletion in Inv-CreER targeted CPs leads to BCC in both 264 
ear and tail epidermis (Fig. 5a). In the tail, BCCs were restricted to the interscale 265 
whereas, in the scale, clones only progressed into dysplasia (Fig. 5b-c and Extended 266 
Data Fig.8b). These results indicate that p53 restricts the competence of SmoM2 267 
targeted CPs of the interscale to progress into BCC.  268 
 269 
Although the proportion of clones that progress into BCC continued to be more 270 
frequent and more rapid in K14-CreER targeted SCs, at 24w post-induction more than 271 
half of interscale Inv-CreER targeted clones had progressed into BCC after p53 deletion 272 
(Fig. 5c). The clonal persistence and clone size were increased upon p53 deletion in 273 
both Inv-CreER/Rosa-SmoM2 and K14-CreER/Rosa-SmoM2 interscale clones, 274 
although the clones were still bigger and more persistent in K14 targeted cells (Fig. 5b 275 
and d and Extended Data Fig. 8c-e). These results indicate that, upon p53 deletion, both 276 
oncogene targeted CPs and SCs present an increase in self-renewing divisions allowing 277 
CPs to acquire the competence to form BCC upon SmoM2 expression.   278 
 279 
We next determined whether the observed increase in clone size in the absence 280 
of p53 in CPs and SCs was due to a decrease in apoptosis, an increase in proliferation or 281 
both. Immunostaining for active caspase-3 8w after oncogenic activation showed that 282 
large Inv-CreER/Rosa-SmoM2/p53fl/fl dysplastic and BCC clones displayed reduced 283 
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apoptosis, mirroring our observation in K14-CreER/Rosa-SmoM2 (Extended Data Fig. 284 
8f). However, apoptosis was unchanged in Inv-CreER p53 deficient hyperplastic clones, 285 
suggesting that p53 dependent and independent mechanisms control apoptosis in 286 
oncogene-targeted cells (Fig. 5e and Extended Data Fig. 8g). EdU/BrdU double-pulse 287 
experiments at 12w post-induction showed that deletion of p53 increased the rate of 288 
proliferation in both Inv-CreER and K14-CreER oncogene targeted cells (Fig. 5f). 289 
According to our model, this increase in the rate of division was sufficient, keeping all 290 
other parameters constant, to explain the enhanced tumour growth (Fig. 5g). This 291 
provides additional evidence that growth arrest in oncogene targeted CPs is a key 292 
determinant in their inability to mediate BCC progression in the presence of p53.  293 
 294 
In summary, our results demonstrate that p53 restricts the competence of CPs to initiate 295 
BCC by promoting apoptosis and inducing cell cycle arrest in oncogene targeted CPs.   296 
 297 
Discussion 298 
In this study, we have defined the quantitative dynamics of BCC initiation at single cell 299 
resolution, from the first oncogenic hit to the development of invasive tumours. These 300 
results show that the proliferative hierarchical organization of skin epidermis is a key 301 
determinant of tumour development, with only IFE SCs and not CPs competent to 302 
initiate BCC following oncogenic HH signalling (Extended data Fig. 9). Even though 303 
CP-derived clones survive and proliferate for months, they are surprisingly robust to 304 
BCC transformation and invasion, becoming “frozen” in a pre-tumorigenic state. The 305 
developmental cerebellar progenitors initiate medulloblastoma upon oncogenic HH 306 
signaling17,18, suggesting the developmental stage of progenitors may also dictate 307 
competence for tumour initiation. The apparent long-term maintenance of some 308 
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oncogene targeted CPs stands in contrast to classical transient-amplifying cells in other 309 
compartments, such as hair matrix in the skin or the non-Lgr5 crypt progenitors in gut, 310 
which are resistant to tumour initiation because of their short lifespan19-22.  311 
 312 
Our results show that IFE SCs reside solely in the interscale region, and have the 313 
unique and regionalized competence to initiate large and invasive BCCs. Strikingly, this 314 
regionalized hierarchical organization at homeostasis was maintained upon SmoM2 315 
activation. Oncogene expression in SCs lead to a more rapid clonal expansion as 316 
compared to CPs for two main reasons: the maintenance of hierarchical organization in 317 
early pre-neoplastic lesions, leading to increased symmetric self-renewing divisions; 318 
and the combined resistance to apoptosis and enhanced proliferation of SC-derived pre-319 
neoplastic lesions, leading to a larger effective growth rate. These two properties allow 320 
SC-targeted tumours to escape the frozen-state that characterized CP-targeted pre-321 
neoplastic lesions, and thereby progress to an invasive phenotype.  322 
 323 
Finally, our results show that p53 restricts the competence of CPs to undergo 324 
BCC initiation by promoting apoptosis and inducing cell cycle arrest in oncogene 325 
targeted CPs. Interestingly, although the division rates of CPs and SCs deficient for p53 326 
are similar, SC-targeted tumours still grow to larger sizes than CP-targeted tumours, 327 
suggesting that the hierarchical organization is at least partially maintained even after 328 
two oncogenic hits. By establishing that sustained imbalance towards self-renewing 329 
divisions and resistance to p53 mediated apoptosis and cell cycle arrest are the main 330 
drivers of tumorigenesis, this study suggests that therapy promoting differentiation, p53 331 
reactivation and apoptosis could present a promising avenue to promote BCC regression 332 
and prevent tumour relapse.  333 
334 
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FIGURE LEGENDS 421 
Figure 1. SCs but not CPs are competent to initiate BCC formation upon HH 422 
activation 423 
(a) Genetic strategy to activate SmoM2 expression in SCs and CPs. (b) Immunostaining 424 
of β4-integrin/SmoM2 in ear and tail skin 24w after SmoM2 activation. (c) 425 
Immunostaining of β4-integrin/K14 in ventral skin  24w after Ptch1 deletion. (d) 426 
Quantification of tumour burden (total tumour area divided by length of epidermis) 427 
following Ptch1 deletion. Quantification of BCC number per length (mm) following 428 
Ptch1 deletion. (n=4 Inv-CreER/Ptch1KO animals and n=3 K14CreER/Ptch1KO 429 
animals (e) Immunostaining of K31/ SmoM2 in whole mount tail skin. (f) 430 
Quantification of the morphology of SmoM2-expressing clones. Description of number 431 
of counted clones is found in the method section. Hoechst nuclear staining in blue; scale 432 
bars, 100μm. *P≤0,05, **P≤0,01, ***P≤0,001. Histograms and error bars represent the 433 
mean and the standard error of the mean (s.e.m). 434 
 435 
 436 
Figure 2: Homeostatic renewal of mouse tail epidermis. 437 
 (a, b) Distribution of basal clone sizes, in K14-CreER/Rosa-YFP (a) and Inv-438 
CreER/Rosa-YFP (b) epidermis. The number of clones analysed is indicated for each 439 
time point and in the method section. (c) Mean basal (top) and suprabasal (bottom) 440 
clone size in the interscale. The lines represent the model fit. (d) Cell fate probabilities 441 
of SCs and CPs in the interscale, as extracted from the fits. (e) Clonal persistence (top) 442 
and labelled cell fraction (bottom) in the interscale. Description of number of counted 443 
clones is found in the method section. The lines are the predictions from the model 444 
using only the parameters extracted in d. K14-CreER/Rosa-YFP clones display a net 445 
expansion, whereas Inv-CreER/Rosa-YFP clones display a net contraction. Histograms 446 
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and error bars represent the mean and the s.e.m. Shaded areas represent 95% confidence 447 
intervals for the model prediction (Supplementary Theory). 448 
 449 
 450 
Figure 3: SmoM2 expression in CPs induces clonal expansion that does not 451 
progress into BCC. 452 
(a) Immunostaining for β-integrin, YFP and SmoM2 in Inv-CreER/Rosa-YFP and 453 
Inv-CreER/Rosa-SmoM2 epidermis at different time points.(b) Distribution of Inv-454 
CreER/Rosa-YFP and Inv-CreER/Rosa-SmoM2 basal clone sizes. The number of 455 
clones analysed in Inv-CreER/Rosa-SmoM2 is indicated for each time point and for 456 
Inv-CreER/Rosa-YFP indicated in Fig. 2b. (c) Quantification of EdU/BrdU double-457 
labelled cells during continuous BrdU administration, at different time points post 458 
clonal induction. The lines represent the model fit (Supplementary Theory). (d) 459 
Quantification of the proportion of apoptotic cells in dysplastic, hyperplastic and 460 
normally differentiating Inv-CreER/Rosa-SmoM2 clones 8w post-induction (n= 73 461 
clones analysed from 4 independent experiments). (e) Division rate determined from 462 
EdU/BrdU double-labelling experiments (data in black, fit in blue dashed line). (f) 463 
Mean basal and suprabasal clone size in the interscale. The lines represent the model fit 464 
from which we inferred the cell fate probabilities displayed in g. (g) Cell fate 465 
probabilities of the tumour progenitor expressing SmoM2. (h) Basal clone size 466 
distribution of Inv-CreER/Rosa-SmoM2 clones (black). Consistent with the hypothesis 467 
of a single equipotent progenitor pool, all distributions are well-fit by single 468 
exponential. Blue lines represent the model prediction using only the parameters 469 
extracted from g. Shaded areas represent 95% confidence intervals for the model 470 
prediction. D: dysplasia; H: hyperplasia; N: normal differentiation. Hoechst nuclear 471 
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staining in blue; scale bars, 10μm. Histograms and error bars represent the mean and the 472 
s.e.m .  473 
 474 
 475 
Figure 4:  SmoM2 expression in SCs induces tumour SCs that lead to BCC 476 
formation.  477 
(a) Immunostaining for β-integrin, YFP and SmoM2 in K14-CreER/Rosa-YFP and 478 
K14-CreER/Rosa-SmoM2 epidermis at different time points. (b) Distribution of K14-479 
CreER/Rosa-YFP and K14-CreER/Rosa-SmoM2 basal clone sizes. The number of 480 
clones analysed for K14-CreER/Rosa-SmoM2 is indicated and for K14-CreER/Rosa-481 
YFP indicated in Fig. 2a. (c) Quantification of EdU/BrdU double-labelled cells 482 
following continuous BrdU administration, at 8w post clonal induction for small K14-483 
CreER clones, Inv-CreER clones, and large K14-CreER clones. (d) Quantification of 484 
the number of apoptotic cells in BCC, dysplastic, hyperplastic and normally 485 
differentiating K14-CreER/Rosa-SmoM2 clones 8w post-induction (n= 117 clones 486 
analysed from 4 independent experiments). (e) Division rate in large K14 clones 487 
determined from double-labelling experiments (data in black, fit in red dashed line). (f) 488 
Whisker plot of the mean basal clone size in the interscale. The boxes delineate the first 489 
and third quartiles of the data, while the whiskers delineate the first and last decile of 490 
the data. The thick continuous line is the best fit from the model from which we extract 491 
the probability of fate choices in tumour SCs and progenitors displayed in g. The thin 492 
dashed lines represent the predicted mean clone sizes of SCs- (top thin curve) and 493 
progenitors- (bottom thin curve) derived clones alone. (g) Cell fate probabilities of the 494 
tumour SC upon SmoM2 activation. (h) Basal clone size distribution of 495 
K14CreER/SmoM2 clones (black). Red lines are the model prediction using only the 496 
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parameters extracted from g. Shaded areas represent 95% confidence intervals for the 497 
model prediction. BCC: basal cell carcinoma; D: dysplasia; H: hyperplasia; N: normal 498 
differentiation. Hoechst nuclear staining in blue; scale bars, 10μm. Histograms and error 499 
bars represent the mean and the s.e.m..  500 
 501 
 502 
Figure 5: p53 deletion in CPs leads to BCC formation. 503 
(a) Immunostaining of β4-integrin/SmoM2 in ear and tail skin of K14 and Inv-504 
CreER/Rosa-SmoM2/p53fl/fl mice 24w after Tamoxifen administration (b) Whole 505 
mount immunostaining of K31/SmoM2 in tail epidermis overtime. (c) Quantification of 506 
normal, hyperplastic, dysplastic and BCC clones in the interscale region. Description of 507 
number of counted clones is found in the method section. (d) Distribution of basal clone 508 
sizes in K14 and Inv-CreER/Rosa-SmoM2/p53fl/fl mice. The number of clones 509 
analysed is indicated. Clone merger events were observed after 12w following 510 
oncogenic activation in K14Cre-ER/Rosa-SmoM2/p53fl/fl preventing the accurate 511 
quantification of clonal persistence and clone size at longer times. (e) Quantification of 512 
the proportion of apoptotic cells in different clones (K14 n= 82 clones and Inv n=90 513 
clones from 3 independent experiments). (f) Percentage of double-labelled EdU/BrdU 514 
SmoM2-expressing cells after 6 days of continuous BrdU administration following a 515 
24h pulse of EdU at 12w post-induction. *P≤0,05, **P≤0,01. (i) Mean basal clone size 516 
in Inv-CreER/Rosa-SmoM2/p53fl/fl and K14-CreER/Rosa-SmoM2/p53fl/fl clones. The 517 
prediction of the model is indicated by the blue and red lines. Histograms and error bars 518 
represent the mean and s.e.m. Shaded areas represent 95% confidence intervals for the 519 
model prediction in i. Scale bars, 100μm.  520 
521 
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METHODS  522 
Mice 523 
K14CREER transgenic mice23 were kindly provided by Elaine Fuchs, The Rockefeller 524 
University; INVCREER were generated in our laboratory8. Ptch1 flox/flox mice 24 and 525 
Rosa–SmoM2–YFP mice25 were obtained from the JAX repository. p53fl/fl26 mice 526 
were obtained from the National Cancer Institute at Frederick.  527 
Mouse colonies were maintained in a certified animal facility in accordance with 528 
European guidelines. Experiments involving mice presented in this work were approved 529 
by Comité d’Ethique du Bien Être Animal (Université Libre de Bruxelles) under 530 
protocol number 483N, that states that animals should be euthanized if they present 531 
tumours that exceed 1cm in diameter. The BCCs observed in this study were 532 
microscopic and ranged from 1.5 mm to 100μm in diameter and in none of the 533 
experiments performed, the tumours exceeded the limit described in protocol 483N. 534 
Female and male animals have been used for all experiments and equal animal gender 535 
ratios have been respected in the majority of the analysis, analysis of the different 536 
mutant mice was not blind and sample size was calculated to reach statistical 537 
significance. 538 
 539 
Skin tumour induction and clonal YFP expression 540 
For clonal induction 3-months-old mice were used. K14CreER/Rosa-YFP, 541 
K14CreER/Rosa-SmoM2, K14CreER/SmoM2/p53fl/fl and K14CreER-Ptch1fl/fl mice 542 
received an intraperitoneal injection of 0,1mg of Tamoxifen and Inv-CreER/Rosa-YFP, 543 
Inv-CreER/Rosa-SmoM2, Inv-CreER/Rosa-SmoM2/p53fl/fl and INVCreER-Ptch1fl/fl 544 
received a intraperitoneal injection of 2.5mg of Tamoxifen to achieve similar level of 545 
recombination in the different models (Extended Data Figure 1a). Mice were sacrificed 546 
and analysed at different time points following Tamoxifen administration. 547 
 548 
Immunostaining in sections  549 
The tail, ventral skin and ear skin were embedded in optimal cutting temperature 550 
compound (OCT, Sakura) and cut into 5–8μm frozen sections using a CM3050S Leica 551 
cryostat (Leica Microsystems).  552 
Immunostainings were performed on frozen sections. Owing to the fusion of SmoM2 553 
with YFP, SmoM2-expressing cells were detected using anti-GFP antibody. Frozen 554 
sections were dried and then fixed with 4% paraformaldehyde/PBS (PFA) for 10min at 555 
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room temperature and blocked with blocking buffer for 1h (PBS, horse serum 5%, BSA 556 
1%, Triton 0.1%). Skin sections were incubated with primary antibodies diluted in 557 
blocking buffer overnight at 4 ◦ C, washed with PBS for 3 × 5 min, and then incubated 558 
with Hoechst solution and secondary antibodies diluted in blocking buffer for 1h at 559 
room temperature. Finally, sections were washed with PBS for 3 × 5 min at room 560 
temperature and mounted in DAKO mounting medium supplemented with 2,5% Dabco 561 
(Sigma). Primary antibodies used were the following: anti- GFP (Rabbit, 1/1000, BD, 562 
ref. A11122), anti-K14 (Chicken, 1/4000, Covance, ref. PCK-153P-0100) and anti-B4-563 
integrin(Rat, 1:200, BD, ref.553745). The following secondary antibodies were used: 564 
anti-rabbit, anti-rat, anti-chicken, conjugated to AlexaFluor488 (Molecular Probes) and 565 
to rhodamine Red-X (JacksonImmunoResearch). Images of the immunostainings in 566 
sections were acquired using an Axio Imager M1 microscope, an AxioCamMR3 camera 567 
and the Axiovision software (Carl Zeiss).  568 
 569 
Immunostaining in whole mounts 570 
Whole mounts of tail epidermis were performed as previously described27 and used to 571 
quantify the proportion of surviving clones ( Extended Data Fig.2b) as well as the basal 572 
suprabasal and total clone size. Specifically, pieces of tail were incubated for 1h 37OC 573 
in EDTA 20mM in PBS  in rocking plate, then using forceps the dermis and epidermis 574 
were separated and the epidermis was fixed for 30 minutes in PFA 4% in agitation at 575 
room temperature and washed 3 times with PBS. 576 
For the immunostaining: tail skin pieces were blocked with  blocking buffer for 3h 577 
(PBS, horse serum 5%, Triton 0.8%) in a rocking plate at room temperature. After, the 578 
skin pieces were incubated with primary antibodies diluted in blocking buffer overnight 579 
at 4 ◦ C, the next day they were washed with PBS-Tween 0.2% for 3 × 10 min at room 580 
temperature, and then incubated with the secondary antibodies diluted in blocking 581 
buffer for 3h at room temperature, washed 2x10 min with PBS-Tween 0.2% and washed 582 
for 10min in PBS. Finally, they were incubated in Hoechst diluted in PBS for 30 583 
minutes at room temperature in the rocking plate, washed 3x10 min in PBS and 584 
mounted in DAKO mounting medium supplemented with 2,5% Dabco (Sigma). 585 
Primary antibodies used were the following: anti-GFP (Rabbit, 1/100, BD, ref. 586 
A11122), anti-GFP (Goat, 1:800,Abcam, ref. Ab6673), anti-active-caspase3 (Rabbit, 587 
1/600,R&D, ref. AF835), anti-β4-integrin(Rat, 1:200, BD, ref. 553745) and anti-K31 588 
(Guinea Pig, 1:200, Progen, ref. GP-hHa1). The following secondary antibodies were 589 
 24
used: anti-rabbit, anti-rat, anti-chicken, anti-goat and anti-guinea pig, conjugated to 590 
AlexaFluor488 (Molecular Probes), to rhodamine Red-X (JacksonImmunoResearch) 591 
and to Cy5 (1:400, Jackson ImmunoResearch). 592 
 593 
Analysis of clone survival, size and apoptosis 594 
Quantification of the proportion of surviving clones, as well as, total and basal clone 595 
size was determined by counting the number of SmoM2-YFP and YFP-positive cells in 596 
each clone using whole-mount tail epidermis. The different clones were imaged using 597 
Z-stacks using a confocal microscope LSM 780 (Carl Zeiss) and orthogonal views were 598 
used to count the number of basal and total number of SmoM2-YFP or YFP-positive 599 
cells in each clone, as well as, the number of active-caspase3 positive cells in each 600 
clone. K31 staining was used to classify the clones according to their location in the 601 
scale or interscale regions. 602 
 603 
Proliferation assays 604 
To measure the kinetics of cell proliferation, a 24h continuous pulse of EdU followed 605 
with a continuous pulse of BrdU were performed. Specifically, mice received at t=0 an 606 
intraperitoneal injection of EdU (1mg/ml) and 0.1mg/ml EdU was added to their 607 
drinking water for 24h.  The next days the mice received a daily intraperitoneal 608 
injection of BrdU (10mg/ml) and 1mg/ml of BrdU was added to their drinking water 609 
during the 8 days of the continuous BrdU pulse. Mice were sacrificed at different time 610 
points and whole mount stainings for the tail were performed. The pieces of tail were 611 
first stained for anti-GFP  (following the protocol described in the previous section). 612 
Secondly, EdU staining was performed following the manufacturer’s instructions 613 
(Invitrogen). The pieces of tail were then washed in PBS and fixed again in PAF 4% for 614 
10 minutes. After they were washed in PBS, blocked for 3h in the blocking buffer and 615 
incubated for 20 min in HCl 1 N at 37 °C, washed three times with PBS-Tween 0.2% 616 
and incubated overnight with Alexa 647-coupled anti-BrdU antibody (mouse, 1:200, 617 
BD). The next day the tail pieces were washed in PBS, incubated in Hoechst for 30 618 
minutes at room temperature in the rocking plate, washed 3x10 min in PBS and 619 
mounted in DAKO mounting medium supplemented with 2,5% Dabco (Sigma).  To 620 
quantify the number of cells that incorporated EdU and/or  BrdU, Z-stacks were 621 
acquired for each individual clone and orthogonal views used to count. 622 
 623 
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Immunohistochemistry  624 
 625 
For p53 immunohistochemistry, 4-μm paraffin sections were deparaffinized, rehydrated, 626 
followed by   antigen unmasking performed for 20 min at 98°C in citrate buffer (pH 6) 627 
using the PT module. Endogenous peroxydase was blocked using 3% H2O2 (Merck) in 628 
methanol for 10 min at room temperature. Endogenous avidin and biotin were blocked 629 
using the Endogenous Blocking kit (Invitrogen) for 20 min at room temperature. In p53 630 
staining, nonspecific antigen blocking was performed using M.O.M. Basic kit reagent. 631 
Mouse anti-p53 antibody (clone 1C12; Cell Signaling) was incubated overnight at 4°C. 632 
Anti-mouse biotinylated in M.O.M. Blocking kit, Stan- dard ABC kit, and ImmPACT 633 
DAB (Vector Laboratories) was used for the detection of HRP activity. Slides were then 634 
dehydrated and mounted using SafeMount (Labonord).  635 
 636 
Supplemental statistics 637 
For the quantification of the clone morphology of SmoM2-expressing clones in the 638 
scale and interscale regions (Fig.1f), we counted in K14-CreER/Rosa-SmoM2 mice, 639 
128,109,76,195,168 and 142 clones in the interscale region ; 141,116,74,94,78 and 69 640 
clones in the scale region from 3,4,4,6,4 and 5 independent experiments at 1,2,4,8,12 641 
and 24 w respectively. In Inv-CreER/Rosa-SmoM2 mice, 104,78,42,127,160 and 344 642 
clones were counted in the interscale region;  94,54,99,90,99 and 39 clones in the scale 643 
region  from 4,4,4,5,4, and 8 independent experiments at 1,2,4,8,12,24 w respectively.  644 
 645 
For the analysis of the clone size of the K14-CreER/Rosa-YFP mice (Fig. 2a,c and 646 
Extended Data Fig. 2), we counted clones (both in scale and interscale) from two 647 
independent experiments at 1w and 2w, five independent experiments at 4w, three 648 
independent experiments at 8w, two independent experiments at 12w and four 649 
independent experiments at 24 w. For the analysis of the clone size of the Inv-650 
CreER/Rosa-YFP mice (Fig. 2b-c, Extended Data Fig. 2), we counted clones (both in 651 
scale and interscale) from two independent experiments at 1w and 2w, five independent 652 
experiments at 4w, three independent experiments at 8w, four independent experiments 653 
at 12w and three independent experiments at 24 w ( see Data Source) .  654 
 655 
For the clonal persistence of the K14-CreER/Rosa-YFP mice (Fig. 2e and Extended 656 
Data Fig.2), we counted 167,176,129,100,47,246 clones in interscale and 657 
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184,109,75,66,19,103 clones in scale from 4,5,5,5,2,4, independent experiments at 658 
1,2,4,8,12,and 24 w respectively. For 24w, we counted several areas per mice as the 659 
number of clones was reduced (see Data Source). 660 
For the clonal persistence of the Inv-CreER/Rosa-YFP mice (Fig. 2e and Extended Data 661 
Fig.2), we counted 138,95,25,31,76,54 clones in interscale and 12,17,7,8,20,10 clones 662 
in scale from 2,4,2,3,4,and 3 independent experiments at 1,2,4,8,12 and 24 w 663 
respectively. For 12 and 24w, we counted several areas per mice as the number of 664 
clones was low ( see Data Source) 665 
 666 
For the analysis of the clone size of the Inv-CreER/Rosa-SmoM2 mice (Fig. 3b,f, h, 667 
Extended Data Fig. 5-6), we counted clones (both in scale and interscale) from two 668 
independent experiments at 1w and 2w, from 4 independent experiments at 4w, from 6 669 
independent experiments at 8w, from 6 independent experiments at 12w and from 4 670 
independent experiments at 24 w. 671 
For the clonal persistence of the Inv-CreER/Rosa-SmoM2 mice (Extended Data Fig 5-672 
6), we counted 65,39,71,51,27,18 clones in interscale and 67,27,47,31,12 and 6 clones 673 
in scale from 2,2,4,3,2 and 2 independent experiments at 1,2,4,8,12 and 24w 674 
respectively. 675 
For the analysis of the clone size of the K14-CreER/Rosa-SmoM2 mice (Fig. 4b,f, h, 676 
Extended Data Fig 6- 7), we counted clones (both in scale and interscale) from 3 677 
independent experiments at 1w, from 2 independent experiments at 2w, 4w, from 6 678 
independent experiments at 8w, from 4 independent experiments at 12w and from 2 679 
independent experiments at 24w. 680 
For the clonal persistence of the K14-CreER/Rosa-SmoM2 mice (Extended Data Fig.6-681 
7), we counted 122,63,81,79,74 and 68 clones in interscale and 89,46,37,42,31 and 16 682 
clones in scale from 4,3,4,4,4 and 4 independent experiments at 1,2,4,8,12 and 24w 683 
respectively. 684 
 685 
 686 
For the cell proliferation kinetics experiments in the Inv-CreER/Rosa-SmoM2 mice 687 
(Fig. 3c, e): At 4w post-induction, we counted 33 clones from 3 independent 688 
experiments for 2 days of continuous BrdU, 30 clones from 2 independent experiments 689 
for 4 days of continuous BrdU, 33 clones from 2 independent experiments for 6 days of 690 
continuous BrdU. At 8w post-induction, we counted 41 clones from n=3 mice for 2 day 691 
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of continuous BrdU, 16 clones from 2 independent experiments for 4 day of continuous 692 
BrdU, 30 clones from 2 independent experiments for 6 day of continuous BrdU and 24 693 
clones from 2 independent experiments for 8 day of continuous BrdU. At 12w post-694 
induction, we counted 19 clones from 2 independent experiments for 2 day of 695 
continuous BrdU, 26 clones from 2 independent experiments for 4 day of continuous 696 
BrdU, 27 clones from 2 independent experiments for 6 day of continuous BrdU and 31 697 
clones from 2 independent experiments mice for 8 day of continuous BrdU. For the 2w 698 
post-induction data point, we use solely continuous BrdU incorporation, and counted 54 699 
clones from 2 independent experiments. 700 
For the cell proliferation kinetics experiments in the K14-CreER/Rosa-SmoM2 mice 701 
(Fig. 4c,e): At 4w post-induction, we counted 56 clones from 3 independent 702 
experiments for 2 days of continuous BrdU, 39 clones from 3 independent experiments 703 
for 4 days of continuous BrdU, 29 clones from 3 independent experiments for 6 days of 704 
continuous BrdU. At 8w post-induction, we counted 30 clones from 2 independent 705 
experiments for 2 days of continuous BrdU, 25 clones from 2 independent experiments 706 
for 4 days of continuous BrdU, 63 clones from 3 independent experiments for 6 days of 707 
continuous BrdU and 41 clones from 3 independent experiments for 8 days of 708 
continuous BrdU. At 12w post-induction, we counted 20 clones from 2 independent 709 
experiments for 2 days of continuous BrdU, 21 clones from 2 independent experiments 710 
for 4 days of continuous BrdU, 28 clones from 2 independent experiments for 6 days of 711 
continuous BrdU and 26 clones from 2 independent experiments for 8 days of 712 
continuous BrdU. 713 
 714 
For the quantification of the clone morphology in absence of p53 interscale (Fig.5c). 715 
For K14-CreER/Rosa-SmoM2/p53fl/fl mice   186,217,90,343,452 and 543 clones from 716 
3,3,2,3,5 and 5 independent experiments and for Inv-CreER/Rosa-SmoM2/p53fl/fl 717 
95,98,199,271,263 and 210 clones from 3,3,3,4,4 and 4 independent experiments were 718 
analysed at 1,2,4,8,12 and 24 w respectively. In the quantification in the scale region 719 
(Extended Data Fig.8b) for K14-CreER/Rosa-SmoM2/p53fl/fl 178,204,100,132,232 720 
and 120 clones were counted from 3,3,2,3,5,and 5 independent experiments 1,2,4,8,12 721 
and 24 w respectively. For Inv-CreER/Rosa-SmoM2 82,127,167,136,62 and 153 clones 722 
were counted from 2,3,3,4,4 and 5 independent experiments 1,2,4,8,12 and 24 w 723 
respectively. 724 
 725 
 28
 726 
For the cell proliferation kinetics experiments in the Inv-CreER/Rosa-SmoM2/p53fl/fl 727 
mice (Fig. 5f) at 12w post-induction 34 clones from 3 independent experiments were 728 
counted. For the cell proliferation kinetics experiments in the K14-CreER/Rosa-729 
SmoM2/p53fl/fl mice (Fig. 5f) at 12w post-induction 44 clones from two independent 730 
experiments were counted. 731 
 732 
For the clonal persistence experiments in Inv-CreER/Rosa-SmoM2/p53fl/fl, 733 
132,78,68,58 and 89 clones from 4,3,3,3 and 5 independent experiments were counted 734 
at 1,2,4,8,12 and 24 w and in K14-CreER/Rosa-SmoM2/p53fl/fl mice 124,82,53,76 and 735 
100 clones were counted from 4,3,2,3 and 4 independent experiments at 1,2,4,8 and 736 
12w respectively (Extended Data Fig.8e). ( See Data Source) 737 
 738 
 739 
 740 
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Extended Data Figure legends 763 
 764 
Extended data Figure 1. The fate of oncogene targeted clones is determined by the 765 
initial targeted cell (SC or CP) and their location in scale or interscale regions 766 
(a) Orthogonal view used to quantify the number of clones, cells stained with 4-767 
integrin/SmoM2. (left).  Quantification of the number of clones induced 1 week after 768 
Tamoxifen administration in scale and interscale regions in K14-CreER/Rosa-SmoM2 769 
(n=4 animals, 0.1mg Tamoxifen) and Inv-CreER/ Rosa-SmoM2 (n=3 animals, 2.5 mg 770 
Tamoxifen) (right). (b) Immunostaining for β4-integrin and SmoM2 in K14-771 
CreER/Rosa-SmoM2 and Inv-CreER/Rosa-SmoM2 clones located in the scale and 772 
interscale regions, 8w after oncogene activation. (c) Immunostaining for the 773 
differentiation marker keratin-10, K10, and SmoM2 in K14-CreER/Rosa-SmoM2 and 774 
Inv-CreER/Rosa-SmoM2 clones 8w after oncogene activation, showing absence of 775 
differentiated cells in K14-CreER/Rosa-SmoM2 clones and alteration of the 776 
differentiation in Inv-CreER/Rosa-SmoM2 clones. Hoechst nuclear staining is 777 
represented in blue; Scale bars, 10μm. 778 
 779 
Extended data Figure 2. Evolution of K14-CreER/Rosa-YFP and Inv-780 
CreER/Rosa-YFP clones in scale and interscale regions 781 
(a) Whole mount immunostaining for YFP/K31 in K14-CreER/Rosa-YFP mice and Inv-782 
CreER/Rosa-YFP mice upon Tamoxifen administration. (b) Scheme representing the 783 
area of tail epidermis  (area comprised by 6 groups of triplets of hair follicles, 784 
highlighted in black) that is used to quantify the clone number and persistence. (c) 785 
Distribution of K14-CreER/Rosa-YFP and Inv-CreER/Rosa-YFP total clone sizes as 786 
measured by total cell content of surviving clones, imaged by confocal microscopy on 787 
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whole-mount tail epidermis from 1 to 24 weeks following Tamoxifen administration. 788 
The number of analyzed clones is indicated for each time point. Hoechst nuclear 789 
staining is represented in blue; scale bars, 100μm. Histograms and error bars represent 790 
the mean and the standard error of the mean (s.e.m) 791 
 792 
 793 
  794 
  795 
Extended data Figure 3. The interscale is maintained by two cell populations 796 
during homeostasis. 797 
(a) Evolution in time of the total labelled cell fraction under three hypotheses. For a 798 
perfect single population of equipotent balanced progenitors, the labelled cell fraction 799 
remains constant. For a single population of equipotent balanced progenitors displaying 800 
short-term priming, the labelled cell fraction increases transiently for the cells primed to 801 
divide, and decreases transiently for the cells primed to differentiate, but after the 802 
priming period, both fractions remain constant at different values. For two populations 803 
organised in a hierarchy, the labelled fraction of the progenitors decreases continuously 804 
to zero, while the labelled fraction of the stem cells continuous increases to reach a 805 
steady state value, corresponding to its average progeny size. (b) Cumulative basal 806 
clone size distribution of Inv-CreER/Rosa-YFP clones at homeostasis in the interscale 807 
upon Tamoxifen administration. (c) Cumulative basal clone size distribution of K14-808 
CreER/Rosa-YFP clones at homeostasis in the interscale upon Tamoxifen 809 
administration. Clonal distributions are plotted in log-plot, error bars indicate S.D., 810 
thick lines are the model prediction and shaded area indicate 95% confidence intervals 811 
in the model prediction. 812 
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 813 
 814 
 815 
  816 
Extended data Figure 4. The scale is maintained by a single population during 817 
homeostasis. 818 
(a) Evolution of mean surviving basal (top) and suprabasal (bottom) clone size in the 819 
scale for K14-CreER/Rosa-YFP (red) and Inv-CreER/Rosa-YFP (blue). In contrast to 820 
the interscale, in the scale K14- and Inv-CreER clones behave identically, indicative of 821 
a single progenitor pool. The lines are the fit from the model from which we extract the 822 
fate choices of progenitors displayed in b. (b) Fate choices of the equipotent progenitor 823 
pool in the scale, as extracted from the fits. (c) Clonal persistence (top) and labelled cell 824 
fraction (bottom) in the scale for K14-CreER/Rosa-YFP (red) and Inv-CreER/Rosa-825 
YFP (blue). The blue and red lines are the predictions of the model (see Supplementary 826 
Notes for details) using only the parameters extracted in b. K14- and Inv-CreER clones 827 
behave similarly and display near-perfect long-term balance. For the clonal persistence 828 
data, we examined in each mouse a randomly chosen area shown in Extended data Fig. 829 
2b. Error bars represent the s.e.m. (d) Cumulative basal clone size distribution of K14-830 
CreER/Rosa-YFP clones at homeostasis in the scale upon Tamoxifen administration. 831 
One should note that there were too few Involucrin clones in the scale to plot 832 
meaningful distributions. Clonal distributions are plotted in log-plot, error bars indicate 833 
S.D, thick lines are the model prediction and shaded area indicate 95% confidence 834 
intervals in the model prediction. 835 
 836 
Extended data Figure 5. Clonal dynamics of interscale InvSmoM2 clones is 837 
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consistent with a single imbalanced population of progenitors slowing down in 838 
time 839 
(a) Distribution of Inv-CreER/Rosa-YFP (black) and Inv-CreER/Rosa-SmoM2 (red) 840 
clone sizes as measured by total cell content, imaged by confocal microscopy on whole 841 
mount tail epidermis from 1w to 24w following Tamoxifen administration. The number 842 
of clones analysed in Inv-CreER/Rosa-SmoM2 is indicated in Fig 3b. The number of 843 
clones counted in Inv-CreER/Rosa-YFP is as indicated in Fig. 2b. (b) Evolution of the 844 
clonal persistence for interscale Inv-CreER/Rosa-SmoM2 clones. (c) Labelled cell 845 
fraction for interscale Inv-CreER/Rosa-SmoM2 clones. (d) Fraction of EdU/BrdU 846 
double-labelled cells as a function of basal clone size at 8w for Inv-CreER/Rosa-847 
SmoM2 clones, for 2 (left), 4 (centre) and 6 (right) days of continuous BrdU 848 
incorporation. (e) Immunostaining for β4-integrin, SmoM2 and active-caspase-3 in Inv-849 
CreER/Rosa-SmoM2 clones at 8w post-induction. (f) Percentage of dysplastic, 850 
hyperplastic and normally differentiating Inv-CreER/Rosa-SmoM2 clones presenting at 851 
least one active-caspase positive cell within the clone at 8w post-induction (n= 73 852 
clones analysed from 4 independent experiments). (g) Quantification of the number (%) 853 
of basal and suprabasal apoptotic cells in dysplastic, hyperplastic and normally 854 
differentiating Inv-CreER/Rosa-SmoM2 clones 8w after SmoM2-activation. (h) 855 
Percentage of dysplastic, hyperplastic and normally differentiating Inv-CreER/Rosa-856 
SmoM2 clones presenting apoptosis in basal and suprabasal compartments 8w after 857 
oncogenic activation. (i) Cumulative distribution of the fraction of basal apoptosis as a 858 
function of basal cell number in an Inv-CreER/Rosa-SmoM2 clone at 8w (data in blue). 859 
The green line is the expected theoretical distribution of apoptotic fraction if apoptosis 860 
occurred randomly (following a Poisson process), in any clone with the same 861 
probability. The data is statistically different from the random theory, showing that 862 
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apoptosis clusters in certain clones at a given time point. (j) Short-term fate outcome of 863 
progenitors in Inv-CreER/Rosa-SmoM2 clones at 8w, as assessed by using EdU as a 864 
clonal marker. We count only cell doublets and classify them as either basal-basal, 865 
basal-suprabasal, or suprabasal-suprabasal. (n=47 clones from 3 independent 866 
experiments). Immunostaining for β4-integrin, EdU and SmoM2 showing the different 867 
type of cell fate outcomes found in Inv-CreER/Rosa-SmoM2 clones.  D: dysplasia; H: 868 
hyperplasia; N: normal differentiation. Hoechst nuclear staining is represented in blue; 869 
Scale bars, 10μm. Histograms and error bars represent the mean and the s.e.m. 870 
 871 
Extended data Figure 6. Clonal dynamics of Inv-CreER/Rosa-SmoM2 and K14-872 
CreER/Rosa-SmoM2 clones in the scale are similar 873 
 (a) Evolution of mean surviving basal clone sizes (top) and labelled cell fraction 874 
(bottom), for K14-CreER/Rosa-SmoM2, in the scale. (b) Evolution of mean surviving 875 
basal clone sizes (top) and labelled cell fraction (bottom), for Inv-CreER/Rosa-SmoM2, 876 
in the scale. Whereas the interscale clones show net expansion, scale clones, both Inv-877 
CreER and K14-CreER, show near balance at the population level. (c) Evolution of the 878 
persistence of K14-CreER/Rosa-SmoM2 (green) and Inv-CreER/Rosa-SmoM2 (purple) 879 
clones in the scale. Strikingly, and in contrast to the interscale, both K14 and Involucrin 880 
clones have the same persistence. (d) Mean basal clone size, normalised by the mean 881 
clone size at 1w for both Inv-CreER and K14-CreER clones. Even though one can see 882 
on panel (a) and (b) that the final clone size is higher in K14, this is fully explained by 883 
short-term differences in fate during the first week indicative of short-term priming for 884 
K14. Correspondingly, the evolution of the labelling fraction is very similar for K14 885 
and Involucrin in scale. Therefore, K14-CreER/Rosa-SmoM2 and Inv-CreER/Rosa-886 
SmoM2 in scale display the same long-term kinetics upon oncogenic activation, 887 
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consistent with the one-population model uncovered at homeostasis. Error bars 888 
represent the s.e.m. 889 
 890 
Extended data Figure 7. Clonal dynamics of interscale K14-CreER/Rosa-SmoM2 891 
clones is consistent with two populations 892 
(a) Distribution of K14-CreER/Rosa-YFP (black) and K14-CreER/Rosa-SmoM2 (red) 893 
clone sizes as measured by total cell content, imaged by confocal microscopy on whole 894 
mount tail epidermis from 1w to 24w post-induction. The number of clones analyzed 895 
for K14-CreER/Rosa-SmoM2 is indicated in Fig 4b; the number of clones counted in 896 
K14-CreER/Rosa-YFP is as indicated in Fig. 2a. (b) Evolution of the clonal persistence 897 
and (c) labelled cell fraction for K14-CreER/Rosa-SmoM2 clones in the interscale. (d) 898 
Fraction of EdU/BrdU double-labelled cells as a function of basal clone size at 8w for 899 
K14-CreER/Rosa-SmoM2 clones, for 2 (left), 4 (centre) and 6 (right) days of 900 
continuous BrdU incorporation. (e) Immunostaining for β4-integrin, SmoM2 and 901 
active-caspase-3 in K14-CreER/Rosa-SmoM2 clones 8w after SmoM2 activation. (f) 902 
Percentage of BCC, dysplastic, hyperplastic and normally differentiating clones 903 
presenting at least one active-caspase-3 positive cell at 8w post-induction (n=117 clones 904 
analysed from 4 independent experiments). (g) Quantification of the number (%) of 905 
basal and suprabasal apoptotic cells in dysplastic, hyperplastic and normally 906 
differentiating Inv-CreER/Rosa-SmoM2 clones 8w after SmoM2-activation. (h) 907 
Percentage of dysplastic, hyperplastic and normally differentiating Inv-CreER/Rosa-908 
SmoM2 clones presenting basal and suprabasal apoptosis 8w after oncogenic activation. 909 
(i) Cumulative distribution of the fraction of basal apoptosis as a function of basal cell 910 
number in a K14-CreER/Rosa-SmoM2 clone at 8w (data in red). The green line is the 911 
expected theoretical distribution of apoptotic fraction if apoptosis occurred randomly 912 
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(following a Poisson process), in any clone with the same probability. The data is 913 
statistically different from the random theory, showing that apoptosis clusters in certain 914 
clones at a given time point. (j) Quantification of EdU/BrdU double-labelled cells as a 915 
function of the period of continuous BrdU incorporation for large K14 clones at 4w 916 
(black), 8w (orange) and 12w (red) post clonal induction. The dashed lines represent the 917 
model fit (Supplementary Theory). (k) Whisker plot of the suprabasal clone size in the 918 
interscale. The boxes delineate the first and third quartiles of the data, while the 919 
whiskers delineate the first and last decile of the data at a given time point. The thick 920 
continuous line is the best fit from the model from which we extract the probability of 921 
fate choices in tumor SC and progenitors, displayed in Fig.4g. The thin lines represent 922 
the mean clone sizes of stem cells (top curve) and progenitors (bottom curve) if they 923 
were alone. (l) Short-term fate outcome of progenitors in K14-CreER/Rosa-SmoM2 924 
clones at 8w, as assessed by using EdU as a clonal marker. We count only cell doublets 925 
and classify them as either basal-basal, basal-suprabasal, or suprabasal-suprabasal. 926 
(n=49 clones from 3 independent experiments) Immunostaining for β4-integrin, EdU 927 
and SmoM2 in K14-CreER/Rosa-SmoM2 hyperplastic/dysplastic clones (top) and in 928 
BCC (bottom panel). BCC: basal cell carcinoma; D: dysplasia; H: hyperplasia; N: 929 
normal differentiation; SB: suprabasal. Hoechst nuclear staining is represented in blue; 930 
Scale bars, 10μm. Error bars represent the s.e.m. 931 
 932 
Extended data Figure 8. Effect of p53 deletion in the cellular dynamics of CPs and 933 
SCs 934 
(a) IHC staining for p53 in Inv-CreER/Rosa-SmoM2 and K14-CreER/Rosa-SmoM2 935 
clones 12 w post-induction (b) Quantification of normal, hyperplastic, dysplastic and 936 
BCC clones in scale region of K14CreER/Rosa-SmoM2/p53fl/fl and Inv-CreER/Rosa-937 
 36
SmoM2/p53fl/fl mice. Description of number of counted clones is found in the method 938 
section.(c) Distribution of clone sizes as measured by total cell content, imaged by 939 
confocal microscopy on whole mount tail epidermis. The number of clones analysed is 940 
indicated in Fig 5d. Clone merger events were observed after 12w following oncogenic 941 
activation in K14Cre-ER/Rosa-SmoM2/p53fl/fl preventing the accurate quantification 942 
of clonal persistence and clone size at long times. (d) Comparison of basal clone size 943 
distribution of Inv-CreER/Rosa-SmoM2/p53fl/fl vs. Inv-CreER/Rosa-SmoM2 and K14-944 
CreER/Rosa-SmoM2/p53fl/fl vs. K14-CreER/Rosa-SmoM2 at 8w and 12w upon 945 
Tamoxifen administration. (e) Evolution of the clonal persistence of Inv-CreER/Rosa-946 
SmoM2/p53fl/fl and K14-CreER/Rosa-SmoM2/p53fl/fl clones. (f) Immunostaining of 947 
active-caspase-3 and SmoM2 8w post-induction in Inv-CreER/Rosa-SmoM2/p53fl/fl 948 
(g) Quantification of the proportion of apoptotic clones in Inv-CreER/Rosa-949 
SmoM2/p53fl/fl (n=90 clones from 3 independent experiments), and K14-CreER/Rosa-950 
SmoM2/p53fl/fl (n=82 animals from 3 independent experiments) 8w post-induction. 951 
Hoechst nuclear staining is represented in blue; Scale bars, 10μm. Error bars represent 952 
the s.e.m. 953 
 954 
Extended data Figure 9. Model of BCC initiation 955 
Activation of SmoM2 in SCs leads to the generation of BCC due to an increase in cell 956 
proliferation and resistance to apoptosis. However, activation of p53 in SmoM2-957 
expressing CPs restricts the progression of dysplastic clones to BCC by promoting 958 
apoptosis and cell cycle arrest.  Deletion of p53 in CPs allows them to progress into 959 
BCC.  960 
 961 
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